Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Receives Consensus Rating of “Hold” from Analysts

Shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) have been given a consensus recommendation of “Hold” by the seven brokerages that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $48.00.

SNSE has been the subject of several recent research reports. Zacks Research upgraded Sensei Biotherapeutics to a “hold” rating in a research note on Tuesday, April 21st. Cantor Fitzgerald restated an “overweight” rating on shares of Sensei Biotherapeutics in a research note on Thursday, June 4th. Citigroup began coverage on shares of Sensei Biotherapeutics in a report on Friday, May 22nd. They issued a “buy” rating and a $55.00 target price on the stock. Wall Street Zen downgraded shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Leerink Partners began coverage on shares of Sensei Biotherapeutics in a report on Monday, April 20th. They set an “outperform” rating and a $50.00 price target for the company.

Insider Activity

In other news, major shareholder James Peyer sold 25,000 shares of Sensei Biotherapeutics stock in a transaction on Monday, June 1st. The shares were sold at an average price of $20.02, for a total transaction of $500,500.00. Following the completion of the sale, the insider directly owned 130,142 shares of the company’s stock, valued at approximately $2,605,442.84. The trade was a 16.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 7.00% of the company’s stock.

Institutional Trading of Sensei Biotherapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE raised its stake in Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after buying an additional 32,719 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Sensei Biotherapeutics by 178.2% during the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after acquiring an additional 20,525 shares in the last quarter. Vivo Capital LLC acquired a new position in shares of Sensei Biotherapeutics during the 1st quarter worth about $22,758,000. Finally, Stempoint Capital LP purchased a new position in shares of Sensei Biotherapeutics in the 1st quarter valued at about $4,188,000. 10.50% of the stock is currently owned by institutional investors and hedge funds.

Sensei Biotherapeutics Stock Performance

The firm has a market capitalization of $18.98 million, a P/E ratio of -0.10 and a beta of -0.25. Sensei Biotherapeutics has a twelve month low of $5.86 and a twelve month high of $36.76. The business has a fifty day simple moving average of $16.69 and a 200-day simple moving average of $19.62.

Sensei Biotherapeutics (NASDAQ:SNSE) last released its earnings results on Friday, May 15th. The company reported ($131.45) EPS for the quarter, missing the consensus estimate of ($0.62) by ($130.83).

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.